|
|
 |
| |
Back to Scientific Program
Back to Annual Meeting
Statin Use Is Associated With Decreased Rate Of Positive Prostate Biopsy
B. Mayer Grob1, Luke Wolfe*2, Tristan T Berry1, Adam P. Klausner1, Vidal M. Despradel1
1Hunter Holmes McGuire Veterans Affairs Hospital, Richmond, VA;2Virginia Commonwealth University Hospitals, Richmond, VA
Introduction: There are early reports that statin use may be associated with decreased rates of several malignancies. We sought to determine whether there was any difference in the rate of positive prostate biopsies in men who were taking statins for dyslipidemia.
Methods: We performed a retrospective review of 105 consecutive men who underwent a prostate biopsy in the work-up for elevated PSA or abnormal digital rectal exam. In addition to statin use, we also analyzed patient age, race, PSA level, ultrasound size, and Gleason score. Chi-square analysis was performed on each variable.
Results: Fifty-eight patients were either on statins at the time of the biopsy or were previously on statins. Forty-seven patients had never been prescribed statins. There was no difference in patient age, median PSA level, median ultrasound size, or race between the two groups. Statin users had a 28% rate of positive biopsies and non-statin users had a 49% rate (p=.0275). While many different statins were in use, 25 patients were on Lovastatin at the time of the biopsy and they had only a 20% positive biopsy rate (p=.022). There was a trend for non-statin users to have a higher percentage of >Gleason 7 cancers 16/23 (70%) compared to statin users 8/16 (50%).
Conclusions: Statin users had a significantly lower percentage of positive prostate biopsies. Lovastatin use was associated with the lowest percentage of positive biopsies. To prove that chemoprevention of prostate cancer with statins is possible, a prospective trial must be undertaken.
Back to Scientific Program
Back to Annual Meeting
|
|
| |
|
|
| |
|
|
|
|
